In late July 2026, headlines said an FDA panel “backed” several popular peptides. That is true, but it is easy to read too much into it. Here is what happened, in plain language.
What the committee was asked
FDA’s Pharmacy Compounding Advisory Committee is a group of outside experts. It advises FDA on which bulk ingredients pharmacies should be allowed to use when they compound medicines for individual patients. Ingredients that qualify go on what is called the 503A bulks list.
On July 23 and 24, 2026, the committee looked at seven peptides: BPC-157, KPV, TB-500, MOTS-c, emideltide (also called DSIP), Semax and epitalon.
How the votes came out
| Panel recommendation | Reported vote | |
|---|---|---|
| BPC-157 | Add to list | 8 to 6, 1 abstention |
| KPV | Add to list | 8 to 6, 1 abstention |
| TB-500 | Add to list | 8 to 6, 1 abstention |
| MOTS-c | Add to list | 7 to 5 |
| Semax | Add to list | Narrow margin |
| Epitalon | Add to list | Narrow margin |
| Emideltide (DSIP) | Do not add | 7 to 6, 1 abstention |
FDA’s own staff scientists had recommended against adding any of the seven. They pointed to a lack of evidence on safety and effectiveness. Several votes were close, which shows the experts did not agree.
What the vote does not do
Advisory votes are recommendations. They do not change the law. For any of these peptides to be legally compounded, FDA would need to accept the advice and then go through formal rulemaking. That usually means a proposed rule, a public comment period and a final rule.
As of October 2026, FDA has not made a final decision. Another committee meeting is planned before the end of February 2027.
How this connects to the April 2026 change
In April 2026, FDA removed 12 peptides, including several of these, from its list of compounding substances that may pose significant safety risks. That happened because the nominations were withdrawn, not because FDA found them safe. Removal alone did not make them eligible for compounding. The July vote was a separate step in a longer process.
What it means for you
- Right now, these peptides have not been added to the 503A bulks list.
- If someone says the vote made a peptide “FDA-approved” or “legal,” that is not accurate.
- Products sold online “for research use only” are a different category. They are not made to medicine standards, and the vote does nothing to change their quality or safety.
- BPC-157 and many related peptides remain banned in sport.
The bottom line
The July vote was a meaningful step, but it was advice, not a final decision. If you are curious about any of these peptides, talk with a clinician or pharmacist about what is known and what is not.